| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Research and development | 922,857 | |||
| General and administrative | 1,020,154 | |||
| Total operating expenses | 1,943,011 | |||
| Loss from operations | -1,943,011 | |||
| Change in fair value of warrant liability | -611 | |||
| Other income (expense), net | 35,224 | |||
| Total other income (expense), net | 35,835 | |||
| Net loss | -1,907,176 | |||
| Deemed dividends | 2,769,742 | |||
| Net loss attributable to common stockholders | -4,676,918 | |||
| Earnings per share, basic, total | -1.77 | |||
| Earnings per share, diluted | -1.77 | |||
| Weighted average number of shares outstanding, basic, total | 2,644,733 | |||
| Weighted average number of shares outstanding, diluted | 2,644,733 | |||
REVELATION BIOSCIENCES, INC. (REVB)
REVELATION BIOSCIENCES, INC. (REVB)